NovoCure (NVCR) Cash from Investing Activities Growth (1y) (2015 - 2026)
NovoCure (NVCR) Cash from Investing Activities Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 0.00% |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn | -117.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.72% |
| Mar 31, 2026 | 219.70% |
| Dec 31, 2025 | 1,614.23% |
| Sep 30, 2025 | 600.83% |
| Jun 30, 2025 | 109.61% |
| Mar 31, 2025 | -102.63% |
| Dec 31, 2024 | -122.55% |
| Sep 30, 2024 | -40.94% |
| Jun 30, 2024 | -2,594.39% |
| Mar 31, 2024 | 199.22% |
| Dec 31, 2023 | 176.92% |
| Sep 30, 2023 | 111.49% |
| Jun 30, 2023 | -108.92% |
| Mar 31, 2023 | 572.64% |
| Dec 31, 2022 | 74.34% |
| Sep 30, 2022 | -149.63% |
| Jun 30, 2022 | 6,049.47% |
| Mar 31, 2022 | -132.14% |
| Dec 31, 2021 | 18.67% |
| Sep 30, 2021 | 105.62% |